Description

CATALYST-β is a dual-mechanism adrenergic activation compound combining Yohimbine (5 mg/mL) and Albuterol (2 mg/mL) to support sympathetic nervous system stimulation and metabolic output.

Yohimbine functions primarily as an alpha-2 adrenergic receptor antagonist. By blocking inhibitory alpha-2 receptors, it may enhance norepinephrine release and increase lipolytic signaling, particularly in areas known to be resistant to fat mobilization.

Albuterol is a selective β2-adrenergic receptor agonist. Activation of β2 receptors increases cyclic AMP (cAMP) signaling, which plays a key role in thermogenesis, metabolic rate elevation, and stimulation of stored fat breakdown.

Together, this combination creates a coordinated adrenergic response:

• Increased sympathetic nervous system activation

• Enhanced lipolytic signaling

• Elevated metabolic output

• Support for thermogenic processes

• Heightened central stimulation and drive

CATALYST-β is positioned as a precision adrenergic activation system within the Entropy Labs metabolic line — engineered for directed thermogenic response and calculated metabolic acceleration.